Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Big pharma goes East: Eli Lilly has signed a major research collaboration and licensing deal with Beijing-based InnoCare Pharma, valued at up to $3.35 billion. The partnership will tap InnoCare's drug discovery platform to develop compounds against up to five targets in cancer and autoimmune diseases. InnoCare stands to receive $100 million upfront, with billions more tied to milestones and royalties.
Big pharma goes East: Eli Lilly and InnoCare team up in a $3.35B drug discovery deal
Eli Lilly has entered into a major research collaboration and licensing agreement with Chinese drugmaker InnoCare Pharma, with the deal valued at up to $3.35 billion. The partnership will leverage InnoCare's drug discovery platform to identify and advance new compounds against up to five therapeutic targets, with a focus on cancer and autoimmune diseases — two of the most active and competitive areas in modern medicine.
InnoCare, headquartered in Beijing, will lead the discovery and development work, while Eli Lilly brings its global commercial reach and development expertise to the table. The specific disease targets haven't been disclosed yet, but the scope of the deal signals serious ambition on both sides.
By the Numbers
Why it matters: This deal reflects a growing trend of Western pharma giants partnering with Chinese biotech firms to access innovative drug discovery capabilities. For patients, it could accelerate the pipeline of new treatments for cancer and autoimmune conditions — two disease areas with enormous unmet need.
